RecruitingNCT06531772

Characteristics and Outcomes of TB and HIV Co-infections


Sponsor

Assiut University

Enrollment

100 participants

Start Date

Sep 1, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

People Living with HIV (PLHIV) are prone to several opportunistic infections depending on the degree of immunosuppression as well as infections prevalent in their geographic area/country. These include a wide variety of mycobacterial diseases, fungal infections, bacterial pneumonias, pneumocystis jirovecii pneumonia, cryptococcal infections, toxoplasmosis etc. Tuberculosis remains the most common opportunistic infection in the developing countries like South Africa and India. HIV and tuberculosis (TB) are two of the most challenging infections faced by the humanity. HIV is the most important risk factor for progression of latent Mycobacterium tuberculosis (MTB) to active disease. The most common cause of death among PLHIV is tuberculosis. These two infections place immense burden on health care systems worldwide. During the last two decades, sustained research and public health initiatives on prevention and therapeutic advances have allayed morbidity and mortality due to HIV and TB to a large extent, however more needs to be done. Globally, an estimated 10 million people fell ill with TB and an estimated 1.4 million people died of TB in 2018 (1.2 million among HIV negative and 251 000 among HIV positive people). There were around 37.9 million PLHIV worldwide in 2018. In the pre-antiretroviral therapy (ART) era, nearly one-third of HIV/AIDS (acquired immune deficiency syndrome) related deaths were due to TB. Wider availability of ART has reduced the mortality of HIV-associated TB significantly, but it still remains high compared to HIV-uninfected individuals. The mortality risk with HIV TB coinfection accounts for approximately 25% of global HIV/AIDS deaths every year. This study aims to investigate characteristics and outcomes of TB and HIV co-infections in Upper Egypt.


Eligibility

Plain Language Summary

Simplified for easier understanding

This study looks at patients who have both tuberculosis (TB) and HIV at the same time — a condition known as TB-HIV co-infection. Researchers want to better understand the characteristics of these patients and how their outcomes differ from people with just one of the two infections. The goal is to improve treatment strategies for people dealing with both diseases together. **You may be eligible if...** - You have been diagnosed in a lab with both TB and HIV at the same time - You are willing to participate and share your health information **You may NOT be eligible if...** - You do not want to take part in the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAntitubercular Agents

Full regimen of antitubercular drugs for 6 month period or longer as justified by patient condition


Locations(1)

Faculty of Medicine, Assiut University

Asyut, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06531772


Related Trials